Brain protective effect of anaesthetics in patients with brain hemorrhage
Not Applicable
- Conditions
- Health Condition 1: I609- Nontraumatic subarachnoid hemorrhage, unspecified
- Registration Number
- CTRI/2024/08/072246
- Lead Sponsor
- ational Institute of Mental Health and Neurosciences (NIMHANS)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients aged 18-65 years with poor grade SAH (World Federation of Neurologic Surgeons [WFNS] grade III-V)
Patients requiring treatment with intra-arterial nimodipine under anaesthesia for a minimum of 3 sessions
Exclusion Criteria
Pregnancy
Patients with established territorial infarct.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in Procaspase-3:cleaved caspase-3 ratio, following repeated exposures among different anaesthetic agentsTimepoint: Before the first and after the last intraarterial nimodpine injection (at baseline and at 5th day)
- Secondary Outcome Measures
Name Time Method [1] Compare the difference in Procaspase-3:cleaved caspase-3 ratio before and after exposure to the individual anaesthetic agents (pre-exposure vs post -exposure difference) <br/ ><br>[2] Compare the CT-scan based cerebral infarct volumes following repeated anaesthetic exposures <br/ ><br>[3] Compare the clinical outcome of patients at discharge (GOSE) following exposure to different anaesthetic agents <br/ ><br>Timepoint: 1.Before the first and after the last intraarterial nimodipine injection <br/ ><br>2. CT scan before and after intrarterial nimodipine injections <br/ ><br> 3. at discharge